Vir Biotechnology: FDA grants fast track to VIR-5500

What happened On Oct 8, 2026, Vir Biotechnology announced that the U.S. Food and Drug Administration has granted Fast Track designation to VIR-5500, a PSMA-targeted PRO-XTEN® dual-masked T-cell engager (TCE), for the treatment of late-line metastatic castration-resistant prostate cancer. The filing states VIR-5500 is being co-developed by Astellas Pharma Inc. and Vir through a global strategic collaboration. The company filed a press release as Exhibit 99.1, which is incorporated by reference.

Key details

• Date of announcement: Oct 8, 2026.
• Product: VIR-5500, described as a PSMA-targeted PRO-XTEN dual-masked T-cell engager (TCE).
• Development: co-developed by Astellas Pharma Inc. and Vir under a global strategic collaboration.
• Documentation: press release filed as Exhibit 99.1; PRO-XTEN® noted as a trademark of Amunix Pharmaceuticals, Inc., a Sanofi company.

Why it may matter This report was made under Item 8.01 (Other events), which covers company announcements of other events disclosed via an 8-K. A filing does not show why the insider traded or why the company acted.